Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Trial ID or NCT#

NCT04002401

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

Official Title

A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Parveen Shiraz, MD
Parveen Shiraz, MD
Blood and marrow transplant specialist, Hematologist-Oncologist
Instructor, Medicine - Blood & Marrow Transplantation
Sally Arai
Sally Arai
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Contact us to find out if this trial is right for you.

Contact

Sharan Claire
650-721-4091

View on ClinicalTrials.gov